SI LA FDA APRUEBA IFINATAMAB DERUXTECAN DE MERCK COMO POSIBLE TRATAMIENTO DE SEGUNDA LÍNEA SMALL CELL LUNG CANCER EXTENSIVE-STAGE EL 10 DE OCTUBRE 2026 ... TARLATAMAB Y IFINATAMAB SERÍAN LOS TRATAMIENTOS ESTÁNDAR EN ESTADOS UNIDOS ... Y LURBINECTEDIN COMO GRAN BATIDO Y NO TENER NI FULL APPROVAL ... ¿ PASARÍA A SER UNA OPCIÓN MUY MINORITARIA EN SEGUNDA LÍNEA ... O A SER RELEGADO A TERCERA LÍNEA ... ? ... VEREMOS .
16 abril 2008
PharmaMar Farmaco Preclinico con actividad en Cancer de Pulmon y Colon .
Cytotoxic-Antineoplastic Derivatives of Prenyl-1,2-naphthohydroquinone
Abstract
Several new prenyl-1,2-naphthohydroquinone derivatives have been prepared by chemical modifications of Diels-Alder products which were obtained from cycloaddition of -myrcene to 1,2-benzoquinone and then evaluated in vitro for their cytotoxic activity against A-549 lung carcinoma, HT-29 colon carcinoma, and MB-231 breast adeno-carcinoma culture cells. Most of them exhibited GI50 values in the M-concentration level.
Abstract
Several new prenyl-1,2-naphthohydroquinone derivatives have been prepared by chemical modifications of Diels-Alder products which were obtained from cycloaddition of -myrcene to 1,2-benzoquinone and then evaluated in vitro for their cytotoxic activity against A-549 lung carcinoma, HT-29 colon carcinoma, and MB-231 breast adeno-carcinoma culture cells. Most of them exhibited GI50 values in the M-concentration level.
Suscribirse a:
Comentarios (Atom)